Barclays Maintains Overweight on Viatris, Raises Price Target to $17

Barclays analyst Glen Santangelo has maintained an Overweight rating on Viatris (NASDAQ: VTRS) and increased the price target from $15 to $17. This adjustment reflects a positive outlook on the company's performance.